114 related articles for article (PubMed ID: 2031191)
1. The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
Newell DR; Mansi J; Hardy J; Button D; Jenns K; Smith IE; Picollo R; Catanese B
Semin Oncol; 1991 Apr; 18(2 Suppl 4):11-7. PubMed ID: 2031191
[TBL] [Abstract][Full Text] [Related]
2. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Mansi JL; de Graeff A; Newell DR; Glaholm J; Button D; Leach MO; Payne G; Smith IE
Br J Cancer; 1991 Sep; 64(3):593-7. PubMed ID: 1911204
[TBL] [Abstract][Full Text] [Related]
3. Single- and multiple dose pharmacokinetics of lonidamine in patients suffering from non-small-cell lung cancer.
Gatzemeier U; Toomes H; Picollo R; Christoffel V; Lücker PW; Ulmer J
Arzneimittelforschung; 1991 Apr; 41(4):436-9. PubMed ID: 1650226
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.
Milane L; Duan ZF; Amiji M
Nanomedicine; 2011 Aug; 7(4):435-44. PubMed ID: 21220050
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs.
Price GS; Page RL; Riviere JE; Cline JM; Thrall DE
Cancer Chemother Pharmacol; 1996; 38(2):129-35. PubMed ID: 8616902
[TBL] [Abstract][Full Text] [Related]
6. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
[TBL] [Abstract][Full Text] [Related]
7. Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer.
Bottalico C; Lorusso V; Brandi M; Micelli G; Rella CA; Coviello M; Atlante AM; Quaranta M; De Lena M
Anticancer Res; 1996; 16(6B):3865-9. PubMed ID: 9042272
[TBL] [Abstract][Full Text] [Related]
8. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH
Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410
[TBL] [Abstract][Full Text] [Related]
9. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Lonidamine after oral administration in cancer patients.
Besner JG; Leclaire R; Band PR; Deschamps M; De Sanctis AJ; Catanese B
Oncology; 1984; 41 Suppl 1():48-52. PubMed ID: 6717895
[TBL] [Abstract][Full Text] [Related]
11. Early observations on the administration of Lonidamine in cancer patients.
Barduagni A; Barduagni M; Di Lauro L; Nardi M; Gallo Curcio C; Tonachella R; Ciottoli GB; Delle Chiaie S
Oncology; 1984; 41 Suppl 1():78-81. PubMed ID: 6717900
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Band PR; Maroun J; Pritchard K; Stewart D; Coppin CM; Wilson K; Eisenhauer EA
Cancer Treat Rep; 1986 Nov; 70(11):1305-10. PubMed ID: 3768873
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial with and without lonidamine in non-small cell lung cancer.
Gatzemeier U; Cavalli F; Häussinger K; Kaukel E; Koschel G; Martinelli G; Neuhauss R; von Pawel J
Semin Oncol; 1991 Apr; 18(2 Suppl 4):42-8. PubMed ID: 1851577
[TBL] [Abstract][Full Text] [Related]
14. Glycosyl and polyalcoholic prodrugs of lonidamine.
Giorgioni G; Ruggieri S; Di Stefano A; Sozio P; Cinque B; Di Marzio L; Santoni G; Claudi F
Bioorg Med Chem Lett; 2008 Apr; 18(7):2445-50. PubMed ID: 18321702
[TBL] [Abstract][Full Text] [Related]
15. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
Weinerman BH; Eisenhauer EA; Besner JG; Coppin CM; Stewart D; Band PR
Cancer Treat Rep; 1986 Jun; 70(6):751-4. PubMed ID: 3524824
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy plus lonidamine in non-small cell lung cancer.
Cionini L
Semin Oncol; 1991 Apr; 18(2 Suppl 4):49-52. PubMed ID: 1851578
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of lonidamine in patients with small cell carcinoma of the lung.
Murray N; Shah A; Band P
Cancer Treat Rep; 1987 Dec; 71(12):1283-4. PubMed ID: 2825992
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
Robins HI; Neuberg DS; Benson AB; Pandya KJ; Tormey DC
Invest New Drugs; 1990 Nov; 8(4):397-9. PubMed ID: 2084074
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
